Game-Changing NanoSphere Products Soon to Disrupt the Oklahoma Cannabis Market
February 5, 2019
— NanoSphere Health Sciences Signs Memorandum of Understanding with
4Evergrn —
DENVER–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NSHS&src=ctag” target=”_blank”gt;$NSHSlt;/agt;–NanoSphere
Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology
leader behind the patented NanoSphere Delivery System™, today signed a
new letter of intent with 4Evergrn LLC, which will bring Evolve
Formulas products to the Oklahoma medical and recreational cannabis
markets. The brand’s pioneering product, the Evolve Formulas Transdermal
NanoSerum™, will hit dispensary shelves in the third quarter of 2019.
Nanosphere Health Sciences has developed the world’s first patented and
clinically-proven delivery system for cannabis. The NanoSphere Delivery
System™ allows producers to nano-encapsulate cannabinoid molecules in
lipid membranes for transportation through the skin and mucosa in the
nose and mouth into the bloodstream within minutes. The result is high
bioavailability, minimal wait-time, precision-metered dosing and
elimination of adverse side effects. This patented technology is the
first and only advanced cannabinoid delivery system and can only be
found in NanoSphere Health products.
The two companies signed a Memorandum of Understanding granting
4Evergreen the limited right in Oklahoma under its patents and other
relevant intellectual property for a License to make, use, distribute
and sell the NanoSphere Delivery System™ through the Evolve brand and
product line.
Since acquiring its patent for the delivery of cannabinoids via
nano-encapsulation in July, 2018, NanoSphere has expanded its operations
through licensing agreements in Colorado, California, Oregon, Canada and
Mexico.
“As a company, we look for partners who hold to a high, pharmaceutical
standard of production and service,” said NanoSphere President and COO
David Sutton. “We have been very impressed by the management and the
operations at 4Evergrn, and we are looking forward to working with them
to bring our cutting-edge solutions to the people of Oklahoma.”
4Evergrn has been awarded a cultivation, processing and dispensary
license by the State of Oklahoma. It has engaged GB Sciences of Las
Vegas, Nevada to design and construct a state-of-the-art facility, using
best practices operating procedures. “Our team at 4Evergrn is passionate
about cutting-edge cannabis development, and our mission is to bring
Oklahomans the best products available in our industry,” said 4Evergrn
CEO Brooklyn Green Clopton. “We believe NanoSphere has developed
something truly revolutionary in terms of providing a better, healthier
product for medical cannabis patients, and we are very excited to be
able to bring this product to market.”
Under the Memorandum of Understanding 4Evergrn will enter into a
36-month, renewable licensing agreement with NanoSphere upon payment of
a $150,000 licensing fee while NanoSphere will provide the equipment and
training necessary to produce the NanoSphere products.
4Evergrn will pay to NanoSphere $4 USD per unit sold for all products
utilizing the Nanosphere Delivery System™.
On behalf of the Board
Robert Sutton, CEO Nanosphere Health Sciences Inc.
Direct:
720.845.1466
Email: rsutton@nanospherehealth.com
About NanoSphere
NanoSphere Health Sciences LLC, is a
biotechnology firm specializing in the creation of the NanoSphere
Delivery System™, a revolutionary platform using nanotechnology in the
biodelivery of supplements, nutraceuticals and over-the-counter
medications for the cannabis, pharmaceutical and animal health
industries, and beyond. For more information on NanoSphere, please visit http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the
world’s first and only scientifically proven nanoparticle delivery
system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™,
is a fast-acting, ultra-strength transdermal formula infused with
nano-encapsulated cannabis and cannabis extracts. For more information
on Evolve Formulas, visit
https://www.evolveformulas.com/. Follow us on
Facebook,
Instagram and
Twitter.
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release
includes forward looking statements that are subject to assumptions,
risks and uncertainties. Statements in this news release which are not
purely historical are forward looking statements, including without
limitation any statements concerning the Company’s intentions, plans,
estimates, expectations or beliefs regarding the future. Although the
Company believes that any forward looking statements in this news
release are reasonable, there can be no assurance that any such forward
looking statements will prove to be accurate. Forward Looking Statements
in this release include the prospect that 4Evergrn LLC will complete the
Licensing Agreement as contemplated in the Memorandum of Understanding,
and failure to do so could affect the outcome expected from this
Agreement. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Without limitation, these include assumptions, risks and uncertainties
inherent in completing sub-licensing arrangements in the United States,
Canada and abroad, product demand, production, competition and
government regulation of the Cannabis industry, any and all of which may
have an adverse effect on the Company’s expansion plans, sales, revenues
and its financial results and condition. Readers are advised to
rely on their own evaluation of such risks and uncertainties and should
not place undue reliance on forward looking statements. Any forward
looking statements are made as of the date of this news release, and the
Company assumes no obligation to update the forward looking statements,
or to update the reasons why actual events or results could or do differ
from those projected in the forward looking statements, whether as a
result of new information, future events or otherwise.
Contacts
Nanosphere Health Sciences Inc.
Robert Sutton, CEO
Direct:
720.845.1466
Email: rsutton@nanospherehealth.com
Investor
Contact:
Victor Goncalves, Executive Vice President
Mobile:
204-997-5517
E-mail: vgoncalves@nanospherehealth.com